News
DGAP-News: Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
DGAP-News: Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic
DGAP-News: PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD
DGAP-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Czech Republic
DGAP-News: HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance
DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022
DGAP-News: Biotest AG: Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG
DGAP-News: Biotest AG: Annual General Meeting approves dividend distribution
DGAP-News: Biotest AG: Biotest records sales of € 115 million in the first quarter of 2022
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005765/en/
Dr. Alessandro Riva (Photo: Transgene)
Transgene
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
This press release is being re-issued to revise the language in the Selling, General and Administrative bullet under Financial Results. That third bullet, third sentence should read: The net
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005641/en/
Tim Van Hauwermeiren, co-founder and CEO of argenx
Epigenomics: Bald wieder frisch kapitalisiert!
Vergangene Woche meldete die kürzlich am vorläufigen Erstattungsvorschlag der staatlichen US-Krankenversicherung "Centers for Medicare & Medicaid Services" gescheiterte Epigenomics (WKN: A11QW5)
Epigenomics: Jetzt droht sogar das Aus!
Erneut gibt es wenig konstruktive News, diesmal aber von Epigenomics (WKN: A11QW5) selbst. Die Gesellschaft informiert heute darüber, dass „bei pflichtmäßigem Ermessen angenommen werden muss, dass
Intercept Pharma: FDA-Entscheidung führt zu Kursabsturz, aber...
Zu den größten Verlierern am US-Aktienmarkt zählt heute das Papier des Biotechnologieunternehmens Intercept Pharmaceuticals (WKN: A1J5U0). Grund hierfür ist eine Entscheidung der US-amerikanischen
Arbutus Biopharma: Kursexplosion dank positiver Studiendaten!
Zu den größten Gewinnern am US-Aktienmarkt zählt heute das Papier der kleinen US-amerikanischen Biotechcompany Arbutus Biopharma (WKN: A14XMD). Grund hierfür ist ein erster wichtiger
Clovis Oncology: Gute News, aber...
Gestern, am Montag, dem 18. Mai erhielt Clovis Oncology (WKN: A1JPJY) eine gute Nachricht von Seiten der US-Arzneimittelaufsichtsbehörde FDA. Denn die FDA gab dem Medikamentenkandidaten Rubraca
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close
EQS-News: Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
EQS-News: Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®